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whereas other researchers were unable to detect a positive effect. 21, 30 Two large trials were conducted in Scandinavia 28 and Italy 16 to test the clinical application of hemodilution as a potential therapy for cerebral ischemia, but no positive results were obtained. However, both studies have been criticized because of the moderate degree of hemodilution achieved and the delay in entering patients in the study. Most previous studies have used hemodiluting agents before 4, 5 and immediately, or within 1 hour, after the onset of ischemia. 21, 25, 32, 33 In a clinical setting, however, it is highly unlikely that hemodilution can be instituted immediately after the onset of cerebral ischemia. Only a few studies have investigated delayed hemodilution after cerebral ischemia. 25, 37 Thus, the purpose of this study was to examine the effect of delayed high-concentration albumin therapy on ischemic injury in a highly reproducible model of middle cerebral artery (MCA) occlusion in rats. 2 
Materials and Methods

Animal Preparation
Eighteen adult male Sprague-Dawley rats weighing 270 to 320 g were denied food overnight but had free access to water. Protocols for these studies were approved by the University of Miami Animal Care and Use Committee. Following intraperitoneal administration of atropine sulfate (0.5 mg/kg), anesthesia was induced with 3.5% halothane in a mixture of 70% nitrous oxide and 30% oxygen. The rats were orally intubated, immobilized by intravenously administered pancuronium bromide (0.6 mg/kg), and mechanically ventilated. Temperature probes were inserted into the rectum and the left temporalis muscle, and separate heating lamps were used to maintain rectal and cranial temperatures at 37 to 37.5˚C. The right femoral artery and vein were catheterized for continuous blood pressure monitoring and periodic blood sampling for arterial gas levels, pH, hematocrit, and plasma glucose (15 minutes before MCA occlusion, at 15, 90, and 110 minutes after MCA occlusion and 15 minutes after MCA suture removal). Rectal temperature and body weight were monitored before MCA occlusion and periodically for 3 days thereafter. The mean arterial blood pressure (MABP) was measured via an indwelling femoral artery catheter connected to a precalibrated pressure transducer and was recorded continuously via polygraph. Serial measurements were made of arterial blood gas levels and pH and plasma glucose.
Experimental Model
The right MCA was occluded for 2 hours by using the intraluminal filament method as described by Zea Longa, et al., 38 and modified by us. 2, 3 Briefly, the right common carotid artery was exposed via a midline neck incision and dissected free of surrounding nerves, the occipital branches of the external carotid artery were coagulated, and the pterygopalatine artery was ligated. A 4-cm length of 3-0 monofilament nylon suture was inserted via the proximal external carotid artery into the internal carotid artery and MCA, a distance of 19 to 20 mm from the common carotid artery bifurcation according to the animal's weight. Prior to use, the tip of the suture was heat-blunted, and a 20-mm distal segment was coated with poly-L-lysine solution (0.1% wt/vol) and dried at 60˚C for 1 hour; we have shown that this coating procedure enhances the reproducibility of the resulting infarct. 2 Following suture placement, the neck incision was closed, the animals were allowed to awaken from anesthesia and were tested using a battery of standardized neurobehavioral tests. 2 
Behavioral Testing
Behavioral tests were conducted in all 18 rats before, during (at 60 minutes), and daily for 3 days after MCA occlusion. The battery consisted of two tests that have been used previously to evaluate various aspects of neurological function: 1) the postural reflex test, developed by Bederson and colleagues 1 to examine upper body posture while the animal is suspended by the tail; and 2) the forelimb placing test, developed by De Ryck, et al., 8 to examine sensorimotor integration in forelimb placing responses to visual, tactile, and proprioceptive stimuli. Neurological function was graded on a scale of 0 to 12 (normal = 0, maximum = 12). The rats that did not demonstrate an initial right upper-extremity paresis were excluded from further study. After 2 hours of MCA occlusion, rats were reanesthetized, the temperature probes were reinserted, and the intraluminal suture was carefully withdrawn.
Drug Administration
Human serum albumin ([HSA], 20% solution, nine animals) or control solution (sodium chloride 0.9%, nine animals) was administered intravenously at a dosage of 1% of body weight at a constant rate for 3 minutes immediately after suture withdrawal following a 2-hour period of MCA occlusion.
Infarct Assessment
The animals were killed 3 days after treatment. The brains were then perfusion-fixed as previously described 24 with a mixture of 40% formaldehyde, glacial acetic acid, and methanol (1:1:8 by volume), and blocks of the tissue were embedded in paraffin. Tenmicron-thick sections of brain were cut in the coronal plane and stained with hematoxylin and eosin. To quantitate infarct volume and depict infarct frequency distribution, histological sections were digitized at nine standardized coronal levels by means of a CCDbased camera system with a macro lens and green filter interfaced with an image analysis system from which data were exported to a workstation for processing. An investigator blinded to the experimental groups delineated the zones of infarction, which were clearly demarcated, as well as the outlines of the left and right hemisphere on each section. Software that we developed was used to 
FIG. 1. A:
Bar graph showing the total corrected infarct volume in HSA-and saline-treated rats (*p Ͻ 0.04). B: Bar graph showing rostrocaudal distribution of the areas of total cerebral hemispheric infarction at nine coronal levels in HSA-and salinetreated rats. Data are presented as the mean Ϯ the SEM for eight animals in each group. Repeated-measures ANOVA revealed a highly significant between-subjects effect for the treatment group (p = 0.02); post hoc Bonferroni tests showed significant intergroup differences (*p Ͻ 0.05) at several coronal levels.
quantitate the outlined areas and compute integrated volumes and infarction frequency distribution. 39 The volume of infarction was calculated as the product of the cross-sectional area for all sections and the distance between the sections. To compensate for brain swelling in the ischemic hemisphere, 31 the infarct volume in each rat was corrected by first computing the volume of the left and right hemispheres and applying the following formula: corrected infarct volume = left hemisphere volume Ϫ (right hemisphere volume Ϫ measured infarct volume). The degree of associated brain edema was determined as the difference in brain volume between the two hemispheres.
Statistical Analysis
Infarct areas were analyzed by repeated-measures analysis of variance (ANOVA) and by post hoc Bonferroni testing, which accounted for multiple comparisons. Total (corrected) infarct volumes, overall brain edema, neurological score, and physiological variables were compared by Student's t-test and were further analyzed by linear regression analysis. The Fisher exact test was used to compare the frequency of infarction between groups. A probability value of less than 0.05 was regarded as significant. Values are presented as the mean Ϯ the standard error of the mean (SEM).
Sources of Supplies and Equipment
The Sprague-Dawley rats were obtained from Charles River Laboratories, Wilmington, MA. Temperature readings were obtained by means of a Mon-a-therm probe (model 7000) purchased from Mallinckrodt, Inc., St. Louis, MO. The Statham pressure transducer (model P23XL) was acquired from Viggo-Spectramed, Inc., Oxnard, CA, and the polygraph (model RS3400) from Gould, Inc., Valley View, OH. The blood gas and pH analyzer (model ABL 330) was manufactured by Radiometer America, Inc., Westlake, OH, and the glucose monitor (model 2300 Stat) by Yellow Springs Instrument Co., Inc., Yellow Springs, OH. The HSA was purchased from Baxter Travenol Laboratory, Deerfield, IL. The Xillix CCDbased camera system, Nikon macro lens and filter, MCID image analysis system, and DEC-Alpha workstation were purchased from Xillix Technologies Corp., Vancouver, BC, Canada; Nikon, Tokyo, Japan; Imaging Research, St. Catherine's, ON, Canada; and Digital Equipment Corp., Maynard, MA, respectively.
Results
General Physiological Parameters
Rectal and cranial (temporalis muscle) temperatures, MABP, and plasma glucose and blood gas levels in the 18 animals studied showed no significant differences between groups (Table 1 ). The hematocrit level in the control group was 38.8 Ϯ 2.2% (baseline) and 39.8 Ϯ 3.2% (15 minutes after saline hemodilution). The hematocrit level in the albumin-treated group was 40.1 Ϯ 1.1% at baseline and was reduced to 25.3 Ϯ 0.3% by HSA treatment (p Ͻ 0.05, Student's t-test).
Neurological Assessment
Contralateral forelimb placing deficits were clearly present at 60 minutes after MCA occlusion in both groups (9 Ϯ 0). The HSA significantly improved the neurological score compared with saline at 24 hours after MCA occlusion (6.4 Ϯ 0.7 and 8.5 Ϯ 0.3, respectively; p Ͻ 0.01) and there was a nonsignificant trend toward better recovery in HSA-treated rats than in the saline-treated control group at 48 and 72 hours.
Infarct Volume and Edema
Treatment with HSA significantly reduced the total (cortical + subcortical) infarct volume (Fig. 1A ) compared with treatment with saline (88.9 Ϯ 17.9 mm 3 vs. 133.8 Ϯ 7.6 mm 3 , respectively; p Ͻ 0.04). Figure 1B demonstrates the rostrocaudal distribution of total infarct areas in both groups. Infarct areas were significantly smaller in HSAtreated rats than in the saline-treated control group at coronal levels five (bregma Ϫ1.3 mm), six (bregma Ϫ1.8 mm), seven (bregma Ϫ3.8 mm), and eight (bregma Ϫ5 mm). When considered separately, cortical infarct volume was significantly reduced by treatment with HSA compared with saline (56.1 Ϯ 24 mm 3 and 128.9 Ϯ 8.9 mm 3 , respectively; p Ͻ 0.01). Figure 2A demonstrates the rostrocaudal distribution of cortical infarct areas in both groups. Infarct areas were significantly smaller in HSAtreated rats than in the saline-treated group at coronal levels five (bregma Ϫ1.3 mm), seven (bregma Ϫ3.8 mm), and eight (bregma Ϫ5 mm). Although striatal infarct volume did not differ significantly between groups, striatal infarct areas were significantly smaller in HSA-treated rats than in the saline-treated group (Fig. 2B) at coronal level six (bregma Ϫ1.8 mm). Figure 3 demonstrates the frequency distribution of cerebral infarction at nine stereotactic levels in rat brains treated with saline and HSA, as well as the results of Fisher's exact test comparing the two groups.
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Delayed albumin therapy of cerebral ischemia Treatment with HSA also significantly reduced brain edema (Fig. 4A ) compared with that seen in saline-treated rats (2.49 Ϯ 1.98% vs. 13.05 Ϯ 2.06%, respectively; p Ͻ 0.002). Figure 4B demonstrates the rostrocaudal distribution of brain edema in both groups. Administration of HSA greatly reduced brain edema at almost every coronal level studied.
Linear regression analyses of the pooled data for the 16 surviving rats revealed highly significant correlations between neurological scores at 24, 48, and 72 hours and brain edema (r = 0.73-0.76, p = 0.001-0.002), total infarct volume (r = 0.82-0.85, p = 0.0001-0.0002), and cortical infarct volume (r = 0.81-0.88, p = 0.0001-0.0003). In contrast, neurological scores were not significantly correlated to striatal infarct volume, and hematocrit level and brain edema showed a significant inverse correlation (r = 0.69, p = 0.01).
Two animals died during the experiment (one from each group, both at 24 hours). Autopsies revealed a large ipsilateral hemispheric infarct and extensive brain edema in both animals.
Discussion
The goal of our study was to determine whether acute but delayed HSA administration was efficacious in protecting the brain after a temporary focal ischemic insult. Our results clearly demonstrate that this form of therapy improves outcome as measured both by neurological score and by final pathological estimation of the size of infarction and the extent of edema. Albumin treatment initiated after 2 hours of MCA occlusion significantly reduced brain infarction (by 34%) and brain edema (by 81%).
Experimental Model and Method of Hemodilution
Experimental MCA occlusion in rats may produce varying volumes of infarction, depending on the strain of rat used, the method of MCA occlusion, and the anatomical location of the occlusion site. 26 In the model of MCA suture occlusion, an additional source of variation in infarct size appears to be related to the extent of insertion of the suture, its size, and other characteristics of the suture itself. In the present study and in recently published observations 2, 3 we have used a poly-L-lysine-coated suture and have found that this method yields reliable and highly consistent results (coefficient of variation of infarct volume, 9%).
Therapy with high-concentration HSA has led to striking hemodilution (fall in hematocrit levels from 32 to 28%). 21, 23 In addition to producing hemodilution, concentrated albumin solutions have important oncotic effects, acting as a dehydrating agent on extravascular cerebral tissues and producing a net movement of water from tissue to blood. Cerebral edema may be prevented or significantly reduced by means of albumin solutions. 9 In the current study, administration of HSA greatly reduced brain edema at almost every brain level examined. Furthermore, there was a highly significant correlation between total infarct volume or brain edema and neurological score at 24, 48, and 72 hours (p Ͻ 0.0002) and between cortical infarction and neurological score at the same intervals FIG. 3 . Frequency distribution of cerebral infarction at nine stereotactic levels in rat brains treated with saline (a) and HSA (b) 2 hours after the onset of temporary MCA occlusion (eight animals in each group). c: Brain slices showing the results of Fisher's exact test comparing the data sets in a and b on a pixel-by-pixel basis. The color bars in panels a and b depict the numbers of animals with infarction at each pixel location (for example, red corresponds to eight animals, yellow to six). In panel c, the color bar shows the degree of statistical significance by depicting the value(p Ͻ 0.0002). These benefits of albumin were manifested without an increase in systemic blood pressure or hypothermia. It is likely that the decrease in blood viscosity achieved by lowering the hematocrit level was central to the therapeutic effect. Because HSA is a remarkable protein that serves numerous functions in the body, other properties may also have contributed to the therapeutic effect. Among the roles of albumin are: 1) the binding and inactivation of toxic products; 2) regulation of plasma and interstitial fluid concentrations of endogenous and exogenously administered substances and drugs; 3) participation in anticoagulation; 4) maintenance of microvascular permeability to proteins; and 5) scavenging of free radicals and prevention of lipid peroxidation. 9 
Neurological Evaluation
Administration of HSA significantly improved the neurological score compared with saline at 24 hours after MCA occlusion, and there was a more prominent trend toward better recovery in the HSA-than in the salinetreated group at 48 and 72 hours. These data are in close agreement with the findings of Wood and Fleischer, 34 who noted significant neurological improvement at 24 hours after hypervolemia induced with the hemodiluting solutions of dextran and/or HSA in alert patients with acute focal cerebral ischemia. A beneficial effect of concentrated albumin solutions in the treatment of cerebral ischemia was found by Matsui and Asano 22 and Cole, et al., 6 whereas other authors were unable to detect a positive effect.
21,30
Rationale for Hemodilution in Ischemia
The concept of therapeutic hemodilution has been extensively studied 35 and is based on the close correlation of hematocrit level and whole blood viscosity. Lowering hematocrit levels results in reduced viscosity and less resistance to blood flow, especially in regions of relative stasis. Arguments favoring hemodilution therapy for cerebral ischemia are based on observations that hemodilution improves cerebral blood flow (CBF) and final clinical outcome in animal models of cerebral ischemia as well as human studies. 14, 20 Experimental studies have demonstrated significant elevations in regional CBF in focally ischemic brain following the acute reduction of hematocrit via hypervolemic or isovolemic infusion of autologous plasma or low-molecular-weight dextran. 25, 32, 33 The demonstration of significant elevations in regional CBF in ischemic but not in normal brain implies that the effect of hypervolemic hemodilution on brain perfusion is greater in regions of low blood flow. 36 The effects of viscosity and oxygen content on CBF have been studied in normal and ischemic rats. 6 The data support the hypothesis that in normal brain both viscosity and oxygen content affect CBF, whereas in ischemic brain a decrease in viscosity, but not in oxygen content, increases CBF. 6 Arguments against hemodilution are based on the poor correlation of CBF and outcome after stroke. Physiological manipulations such as hemodilution, hypervolemia, and hypertension, all of which improve CBF, have nonetheless shown variable degrees of success in affecting outcome following focal cerebral ischemia. 7, 15, 21 In addition, several experimental and clinical reports have drawn attention to the potential risks of raised intracranial pressure and cardiac complications following intravascular volume expansion. 18, 36 Although hemodilution is believed to improve the rheological properties of the microcirculation, the issue of "optimum hematocrit" is far from settled and considerable controversy continues. 27 Wood and Kee 35 concluded that a hematocrit level of 33% is ideal for improving blood flow and maximizing oxygen delivery, although Kusunoki, et al., 19 suggested that the optimum level is closer to 40 to 42%. Other experimental and clinical studies have variously suggested that oxygen transport to the brain is optimum at hematocrit levels of 28%, 23 29 to 32%, 5,20 and 34 to 35%. 10, 25 In the current study, when a hematocrit level of 25% was achieved by using HSA therapy, brain damage was reduced and a highly significant correlation was found between hematocrit level and brain edema (p Ͻ 0.01).
The timing of hemodilution therapy is another important variable. Previous investigations have demonstrated a protective effect when hemodilution is used before 5, 7 or shortly after cerebral artery occlusion. was initiated 1 to 3 hours after the onset of MCA occlusion. 20, 37 By contrast, when administered 6 hours postischemia, hemodilution is not helpful and may be harmful. 37 In our study, hemodilution was started 2 hours after MCA occlusion. This time frame is clinically relevant in that it is logistically difficult to institute therapy any earlier in most patients with acute stroke. 17 It is interesting to note that the duration of hemodilution therapy in experimental stroke studies ranged from 20 minutes to 7 days. [21] [22] [23] 25 It has been suggested that if hemodilution therapy is to be effective, it should be completed during the first few hours after the onset of ischemia.
32,33
Clinical Application
The benefits of hemodilution in patients with cerebral infarction continue to be debated. Although some recent clinical studies have shown that hemodilution is beneficial, 14, 29 two large, multicenter trials undertaken to study the effect of hemodilution in patients with acute stroke failed to show benefit. 16, 28 Although hemodilution alone is unlikely to be a panacea in the treatment of stroke, it is likely that this therapy may be of some benefit, particularly when used in conjunction with other treatments, such as thrombolysis, therapeutic hypothermia, excitatory amino acid antagonism, free radical scavengers, or calcium channel blockers. 12, 13, 15, 17 These therapeutic combinations remain to be tested experimentally and clinically.
Conclusions
The current study strongly supports the beneficial effect of delayed high-concentration albumin therapy in a reproducible model of MCA occlusion in rats. Our results show that hemodilution with albumin decreases focal cerebral ischemic injury as judged by neurological score, infarct size, and brain edema. This neuroprotection was achieved when therapy was initiated 2 hours after the onset of temporary MCA occlusion. These data underscore the possible efficacy of delayed, high-concentration therapy with albumin in patients with acute ischemic stroke.
